Form 4: BioMarin Director Maykin Ho Reports Stock Transactions
SEC Form 4 Filing
Director Maykin Ho reported the acquisition of 4,720 shares of BioMarin Pharmaceutical Inc. common stock and the disposal of 21,360 shares on May 21, 2024.
Summary
- On May 21, 2024, Maykin Ho, a director of BioMarin Pharmaceutical Inc., acquired 4,720 shares of common stock.
- These shares were acquired at a price of $0.
- On the same day, Maykin Ho disposed of 21,360 shares.
- Following these transactions, Maykin Ho beneficially owns 21,360 shares of BioMarin Pharmaceutical Inc.
- The filing also includes a Power of Attorney, effective December 6, 2023, authorizing G. Eric Davis, Tae Sang Yoo, and Eric Fleekop to act on Maykin Ho's behalf for Section 16 filings.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the Securities and Exchange Act of 1934. It provides transparency to the market regarding the actions of company directors.
Stakeholder Impact
- The stock transactions by a director may be of interest to shareholders as it provides insight into the director's view of the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 2023-12-06 | Date of execution for Power of Attorney. |
| 2024-05-21 | Date of stock acquisition and disposal. |
| 2024-05-23 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.